May 13, 2020 / 4:42 PM / 20 days ago

BRIEF-Carmat Gets Approval For Reimbursement Of Its Total Artificial Heart During US Clinical Feasibility Study

May 13 (Reuters) - Carmat SA:

* CARMAT OBTAINS APPROVAL FOR THE REIMBURSEMENT OF ITS TOTAL ARTIFICIAL HEART DURING THE US CLINICAL FEASIBILITY STUDY

* CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) CONFIRMS COVERAGE OF DEVICE AND ROUTINE CARE ITEMS AND SERVICES

* STUDY AIMS TO INCLUDE 10 TRANSPLANT-ELIGIBLE PATIENTS, AND PRIMARY ENDPOINT CORRESPONDS TO PATIENT SURVIVAL AT 180 DAYS AFTER IMPLANT OR SUCCESSFUL HEART TRANSPLANT WITHIN 180 DAYS OF IMPLANT

* WE EXPECT PATIENT ENROLMENT TO BEGIN IN Q4 2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below